RadNet (NASDAQ:RDNT) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

RadNet (NASDAQ:RDNT) announced its quarterly earnings data on Sunday. The medical research company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.08, FiscalAI reports. The firm had revenue of $638.26 million during the quarter, compared to analysts’ expectations of $639.97 million. RadNet had a negative net margin of 0.93% and a positive return on equity of 2.61%. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.20 earnings per share.

RadNet Trading Up 3.1%

Shares of NASDAQ:RDNT opened at $78.38 on Tuesday. RadNet has a 52 week low of $50.82 and a 52 week high of $85.84. The company’s 50 day moving average is $72.64 and its two-hundred day moving average is $65.43. The company has a market cap of $6.17 billion, a PE ratio of -290.29 and a beta of 1.42. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of RadNet in a report on Wednesday, November 4th. Jefferies Financial Group restated a “buy” rating on shares of RadNet in a research note on Friday, July 31st. Truist Financial upped their price objective on RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Barclays increased their price objective on RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, August 28th. Finally, KeyCorp lifted their target price on RadNet from $92.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $90.43.

RadNet News Roundup

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: Adjusted EPS of $0.30 beat the $0.22 consensus by about 35%. Revenue rose 22.1% year over year to $638.3 million, and the company reported record quarterly revenue and adjusted EBITDA. RadNet Q3 results and updated guidance
• Positive Sentiment: RadNet raised its FY 2026 outlook for the third consecutive quarter, with revenue guidance of $2.5 billion–$2.6 billion, versus a consensus estimate around $2.5 billion. Higher guidance signals continued confidence in growth. RadNet Q3 earnings and raised guidance
• Positive Sentiment: An analyst highlighted the ONRAD acquisition as a potential value and growth driver: it expands RadNet’s inpatient presence and geographic reach, and ONRAD’s reported EBITDA margins above 30% could make the deal margin-accretive. Advanced imaging growth, operating leverage and AI-related cost controls were also cited as supporting profitability. Analyst view on RadNet’s earnings and acquisition
• Negative Sentiment: Quarterly revenue of $638.3 million came in slightly below analysts’ $640.0 million estimate, tempering an otherwise strong report. RadNet quarterly earnings report

RadNet Company Profile

RadNet, Inc operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging.

The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

RadNet also develops digital health and artificial intelligence solutions through its subsidiary DeepHealth, including technology intended to support imaging workflows and assist with image analysis.